Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

Мобильная версия

Регистрация Забыли пароль?

Журнал «Здоровье ребенка» Том 17, №5, 2022

Вернуться к номеру

Статус вітаміну D у дівчат-підлітків із синдромом полікістозних яєчників

Статус вітаміну D у дівчат-підлітків із синдромом полікістозних яєчників

Авторы: V.I. Pankiv (1), T.Yu. Yuzvenko (1), I.V. Pankiv (2)
(1) — Ukrainian Scientific and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
(2) — Bukovinian State Medical University, Chernivtsi, Ukraine

Рубрики: Педиатрия/Неонатология

Разделы: Клинические исследования

Версия для печати


Резюме

Актуальність. Синдром полікістозних яєчників (СПКЯ) — розлад, який вражає гіпоталамо-гіпофізарно-яєчникову вісь і призводить до порушень менструального циклу й гіперандрогенії. Дослідження показали, що низький рівень вітаміну D може відігравати певну роль у патогенезі СПКЯ. На сьогодні недостатньо даних щодо зв’язку рівнів вітаміну D у сироватці крові та СПКЯ у дівчат-підлітків. Метою дослідження було порівняння рівнів 25-гідроксивітаміну D у дівчаток-підлітків із СПКЯ і без нього. Матеріали та методи. Учасники були класифіковані як такі, що мають СПКЯ, або як контрольні на основі діагностичних критеріїв National Institutes of Health. Був проведений логістичний регресійний аналіз для порівняння нормального (≥ 30 нг/мл) і низького (< 30 нг/мл) рівнів 25(OH)D у сироватці крові в групі із СПКЯ і контрольній. Дані щодо віку учасниць, процентиля індексу маси тіла (ІМТ), рівня 25(OH)D у сироватці крові й сезону, коли була взята кров, були внесені в базу даних. Результати. 82 учасниці (32 — у групі СПКЯ і 50 — у контрольній) відповідали критеріям включення і були класифіковані за наявністю СПКЯ. Усі учасниці групи із СПКЯ мали показник ІМТ вище від 85-го процентиля. Тому учасники з процентилем ІМТ менше за 85-й у контрольній групі були виключені з аналізу. Середній вік учасників становив 17,3 року. У досліджуваній популяції вірогідне частіше діагностували дефіцит і недостатність вітаміну D. Достатні рівні 25(OH)D були виявлені лише в 7 із 82 учасників (8,5 %). Більшість учасників з ІМТ вище від 95-го процентиля мали дефіцит вітаміну D зі статистичною різницею середніх рівнів 25(OH)D на основі кожної категорії процентиля ІМТ. Дефіцит вітаміну D було відзначено в 65,6 % учасниць із СПКЯ проти 38,0 % учасниць контрольної групи. Середній рівень 25(OH)D у сироватці крові становив 16,02 нг/мл у групі СПКЯ і 22,80 нг/мл у контрольній групі. Різниця в рівнях 25(OH)D між групами була статистично значущою (P = 0,036). Висновки. Дефіцит вітаміну D було відзначено в 65,6 % учасниць із СПКЯ проти 38,0 % учасниць контрольної групи. Середній рівень 25(OH)D у сироватці крові становив 16,02 нг/мл у групі СПКЯ і 22,80 нг/мл у контрольній групі.

Background. Polycystic ovary syndrome (PCOS) is a complex disorder affecting the hypothalamic-pituitary-ovarian axis and leading to menstrual irregularities and hyperandrogenism. Studies have suggested that low vitamin D levels may play a role in the pathogenesis of PCOS. There is currently insufficient data regarding association of serum vitamin D levels and PCOS in adolescent females. The purpose of the study was to compare 25-hydroxyvitamin D levels in adolescent females with and without PCOS. Materials and methods. Participants were categorized as having PCOS or as controls based on National Institutes of Health PCOS diagnostic criteria. Exact logistic regression analysis was done to compare normal (≥ 30 ng/mL) versus low (< 30 ng/mL) serum 25(OH)D levels in the PCOS and control groups. Data regarding the participant’s age, body mass index (BMI) percentile, serum 25(OH)D levels, and the season the blood was drawn were recorded in the database. Results. Eighty-two participants (32 were in the PCOS group and 50 were in the control group) met the inclusion criteria and were categorized as either PCOS or control. All participants in PCOS group had BMI greater than the 85th percentile. Therefore, participants with BMI percentile of less than 85th in the control group were excluded from analysis. The mean age of participants was 17.3 years. Vitamin D deficiency and insufficiency were frequently diagnosed in our study population. Sufficient 25(OH)D levels were found in only 7 of 82 participants (8.5 %). The majority of participants with BMI greater than 95th percentile were vitamin D deficient with statistical difference in mean 25(OH)D levels based on each category of BMI percentile. Vitamin D deficiency was noted among 65.6 % of participants with PCOS versus 38.0 % in the control group. The mean serum 25(OH)D level was 16.02 ng/ml in the PCOS group and 22.80 ng/ml in the control group. The difference in 25(OH)D levels between the groups was statistically significant (P = 0.036). Conclusions. Vitamin D deficiency was noted among 65.6 % of participants with PCOS versus 38.0 % in the control group. The mean serum 25(OH)D level was 16.02 ng/ml in the PCOS group and 22.80 ng/ml in the control group.


Ключевые слова

вітамін D; синдром полікістозних яєчників; підлітки

vitamin D; polycystic ovary syndrome; adolescents

doi: http://dx.doi.org/10.22141/2224-0551.17.5.2022.1520

Introduction

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation [1]. Depending on diagnostic criteria, 6 to 20 % of reproductive aged women are affected [2]. PCOS is a complex disorder affecting the hypothalamic-pituitary-ovarian axis and leading to menstrual irregularities and hyperandrogenism marked by elevated serum androgen levels and clinical features such as hirsutism, acne, or alopecia [3]. 
PCOS is often associated with obesity and insulin resistance leading to metabolic disturbances including impaired glucose tolerance (IGT), type 2 diabetes mellitus (DM), and dyslipidemia with future risk of cardiovascular disease [4]. Other associated health concerns include infertility, endometrial hyperplasia, and cancer. PCOS is a predominant cause of infertility and a common gyne-endocrine disorder affecting 7 to 15 % of women in reproductive age [5].
The aetiology of this syndrome remains largely unknown, but mounting evidence suggests that PCOS might be a complex multigenic disorder with strong epigenetic and environmental influences, including diet and lifestyle factors [6]. 
Recently, it has been reported that vitamin D deficiency was a common complication of PCOS and vitamin D status was associated with reproductive ability, metabolic alterations, and mental health of PCOS patients [7]. The serum cholecalciferol level is correlated with metabolic risk factors in PCOS women [8].
Vitamin D is thought to regulate gene transcription through vitamin D receptors (VDR) that are widely distributed in tissues including ovaries [9]. VDR-related genetic polymorphisms have been linked to serum levels of luteinizing hormone, sex hormone binding globulin, testosterone, and insulin [10]. 
Current literature suggests a correlation between low vitamin D levels and insulin resistance (IR) in women with PCOS [11]. Limited evidence supports beneficial effect of vitamin D supplementation on IR, menstrual dysfunction, and fertility [12–14]. 
Vitamin D deficiency is highly prevalent in infertile PCOS women [15, 16]. Studies hypothesize that vitamin D deficiency in PCOS seems to be associated with obesity [17, 18]. 
There is currently insufficient data regarding association of serum vitamin D levels and PCOS in adolescent females [3]. It is unknown if adolescent females with PCOS have higher prevalence of vitamin D deficiency than do adolescent females without PCOS. 
The purpose of the study was to compare prevalence of vitamin D deficiency in adolescent females with and without PCOS.

Materials and methods

The study sample of adolescent females aged 15–19 years included 82 participants; 32 were in the PCOS group and 50 were in the control group. 
The study was approved by the Ukrainian Research and Scientific Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues institutional review board. Serum 25(OH)D levels were obtained using liquid chromatography-tandem mass spectrometry, which is a standard method at the institutional laboratory. 
Exclusion criteria included history of vitamin D deficiency; current vitamin D supplementation; increased risk of vitamin D deficiency secondary to current medication including steroids, antiretrovirals, antiepileptics, or antifungals; or chronic medical conditions such as chronic kidney disease, osteoporosis, osteopenia, cystic fibrosis, or inflammatory bowel disease. 
Chart review was performed to collect information on menstrual pattern, clinical signs of hyperandrogenemia such as hirsutism, and serum free testosterone level. 
The participants were categorized as in either the PCOS or the control group based on National Institutes of Health (NIH) PCOS diagnostic criteria (chronic anovulation characterized by oligomenorrhea, primary or secondary amenorrhea, clinical or biochemical hyperandrogenemia with exclusion of other mimicking conditions) [19].
All participants in the PCOS group had chronic anovulation with elevated serum free testosterone. Conditions such as hyperprolactinemia, congenital adrenal hyperplasia, thyroid disease, and androgen-secreting tumors were effectively excluded by collecting information on prolactin, 17-hydroxyprogesterone, thyroid-stimulating hormone (TSH), and dehydroepiandrosterone sulfate levels.
Data regarding the participant’s age, body mass index (BMI) percentile, serum 25(OH)D levels, and the season the blood was drawn were recorded in the database. Serum 25(OH)D 
levels were defined as deficient if the levels were 20 ng/ml or less, insufficient if levels were between 21 and 29 ng/ml, and sufficient if levels were 30 ng/ml or greater [20]. BMI percentile was used as a marker for adiposity; using the Centers for Disease Control and Prevention criteria for BMI percentile, participants were categorized as normal (< 85th percentile), overweight (85th–95th percentile), obese (95th–99th percentile), and morbid obese (> 99th percentile) [21]. Serum 25(OH)D levels were compared between the PCOS and control groups based on BMI percentile. 
Statistical Analysis
Logistic regression analysis was done to compare normal (≥ 30 ng/ml) vs low (< 30 ng/ml) serum 25(OH)D levels in the PCOS and control groups. Effects of BMI percentile were controlled in the model. All data management and analyses were carried out using the Statgraphics Plus 5.0 software. Values of P < 0.05 were considered statistically significant.

Results

82 participants (32 were in the PCOS group and 50 were in the control) group met the inclusion criteria and were categorized as either PCOS or control. All participants in PCOS group had BMI percentile greater than the 85th percentile. Therefore, participants with BMI percentile of less than 85th in the control group were excluded for analysis. The mean age of participants was 17.3 years. 
Vitamin D deficiency and insufficiency were frequently diagnosed in our study population. Sufficient 25(OH)D levels were found in only 7 of 82 participants (8.5 %). The majority of participants with BMI greater than 95th percentile were vitamin D deficient with statistical difference in mean 25(OH)D levels based on each category of BMI percentile. 
Vitamin D deficiency was noted among 65.6 % of participants with PCOS versus 38.0 % of participants in the control group (Table 1).
The mean serum 25(OH)D levels was 16.02 ng/ml in the PCOS group and 22.80 ng/ml in the control group. The difference in 25(OH)D levels between the groups was statistically significant (P = 0.036) (Table 2).

Discussion

Our study was devoted to the study of vitamin D levels in adolescent females with PCOS. There was statistically significant difference in mean 25(OH)D levels between the PCOS and control groups. The majority of participants with PCOS were obese with low serum 25(OH)D levels. BMI percentile in adolescents has been found to correlate with 25(OH)D levels.
Vitamin D is fat soluble and regulates numerous processes in adipose tissue and their dysregulation leads to metabolic disorders [22]. Obese individuals may spend less time outdoors with less sun exposure and have insufficient vitamin D biosynthesis in the skin [17]. 
The many PCOS diagnostic models in the adolescent population used in clinical practice, commonly referred to as the NIH criteria, Rotterdam criteria, and androgen excess society criteria [23]. Rotterdam criteria were proposed specific to adolescents that includes the presence of all 3 major criteria: oligomenorrhea or amenorrhea for 2 years after menarche, clinical and biochemical hyperandrogenism, and increased ovarian volume of 10 cm3 or greater in 1 ovary [24]. 
There has been no consensus on diagnostic approach. PCOS falls under the domain of various pediatric subspecialties such as endocrine, adolescent medicine, and gynecology. These specialties often have different approaches to documenting clinical examination findings, androgen panel evaluation, and use of ultrasound when evaluating for PCOS and, ultimately, often subscribe to different PCOS diagnostic recommendations. We chose to use the NIH diagnosis model based on the clinical practice. 
Limitation of the study was that a comparison of serum 25(OH)D levels involving participants with BMI in the normal percentile was not done as there were no normal BMI percentile adolescent females with PCOS in our study. Sample size in each group was smaller than the calculated sample size. A future, large-scale study that includes normal-BMI adolescent females with PCOS would be helpful to determine if there is an association between PCOS and vitamin D.

Conclusions

Vitamin D deficiency was noted among 65.6 % of participants with PCOS versus 38.0 % of participants in the control group.
The mean serum 25(OH)D levels was 16.02 ng/ml in the PCOS group and 22.80 ng/ml in the control group. The difference in 25(OH)D levels between the groups was statistically significant (P = 0.036).
Vitamin D deficiency in adolescent females with PCOS is related to obesity. 
 
Received 21.07.2022
Revised 03.08.2022
Accepted 10.08.2022

Список литературы

  1. Witchel S.F., Oberfield S.E., Peña A.S. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J. Endocr. Soc. 2019. 3(8). 1545-1573. doi: 10.1210/js.2019-00078. PMID: 31384717; PMCID: PMC6676075.
  2. Goodman N.F., Cobin R.H., Futterweit W., Glueck J.S., Legro R.S., Carmina E.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — Part 1. Endocr. Pract. 2015. 21(11). 1291-300. doi: 10.4158/EP15748.DSC. PMID: 26509855.
  3. Sadhir M., Kansra A.R., Menon S. Vitamin D Deficiency among Adolescent Females with Polycystic Ovary Syndrome. J. Pediatr. Adolesc. Gynecol. 2015. 28(5). 378-81. doi: 10.1016/j.jpag.2014.11.004. 
  4. Livadas S., Anagnostis P., Bosdou J.K., Bantouna D., Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World J. Diabetes. 2022. 13(1). 5-26. doi: 10.4239/wjd.v13.i1.5. PMID: 35070056; PMCID: PMC8771268.
  5. Collée J., Mawet M., Tebache L., Nisolle M., Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol. Endocrinol. 2021. 37(10). 869-874. doi: 10.1080/09513590.2021.1958310. 
  6. Escobar-Morreale H.F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 2018. 14(5). 270-284. doi: 10.1038/nrendo.2018.24. 
  7. Mu Y., Cheng D., Yin T.L., Yang J. Vitamin D and Polycystic Ovary Syndrome: a Narrative Review. Reprod. Sci. 2021. 28(8). 2110-2117. doi: 10.1007/s43032-020-00369-2.
  8. Wang L., Lv S., Li F., Yu X., Bai E., Yang X. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China. Front. Endocrinol. (Lausanne). 2020. 11. 171. doi: 10.3389/fendo.2020.00171. PMID: 32296394; PMCID: PMC7136495.
  9. Vulcan T., Filip G.A., Lenghel L.M., Suciu T., Ilut P., Procopciuc L.M. Polymorphisms of Vitamin D Receptor and the Effect on Metabolic and Endocrine Abnormalities in Polycystic Ovary Syndrome: A Review. Horm. Metab. Res. 2021. 53(10). 645-653. doi: 10.1055/a-1587-9336. 
  10. Shi X.Y., Huang A.P., Xie D.W., Yu X.L. Association of vitamin D receptor gene variants with polycystic ovary syndrome: a meta-analysis. BMC Med. Genet. 2019. 20(1). 32. doi: 10.1186/s12881-019-0763-5. PMID: 30764792; PMCID: PMC6376757.
  11. Kaminska K., Grzesiak M. The relationship between vitamin D3 and insulin in polycystic ovary syndrome — a critical review. J. Physiol. Pharmacol. 2021. 72(1). doi: 10.26402/jpp.2021.1.02. PMID: 34099581.
  12. Miao C.Y., Fang X.J., Chen Y., Zhang Q. Effect of vitamin D supplementation on polycystic ovary syndrome: A meta-analysis. Exp. Ther. Med. 2020. 19(4). 2641-2649. doi: 10.3892/etm.2020.8525. PMID: 32256745; PMCID: PMC7086222.
  13. Contreras-Bolívar V., García-Fontana B., García-Fontana C., Muñoz-Torres M. Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice. Nutrients. 2021. 13(10). 3491. doi: 10.3390/nu13103491. PMID: 34684492; PMCID: PMC8539968.
  14. Lerchbaum E., Theiler-Schwetz V., Kollmann M., Wölfler M., Pilz S., Obermayer-Pietsch B., Trummer C. Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial. Nutrients. 2021. 13(2). 547. doi: 10.3390/nu13020547. PMID: 33562394; PMCID: PMC7914670.
  15. Mogili K.D., Karuppusami R., Thomas S., Chandy A., Kamath M.S., Tk A. Prevalence of vitamin D deficiency in infertile women with polycystic ovarian syndrome and its association with metabolic syndrome — A prospective observational study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018. 229. 15-19. doi: 10.1016/j.ejogrb.2018.08.001. PMID: 30096464.
  16. Figurová J., Dravecká I., Javorský M., Petríková J., Lazúrová I. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities. Wien. Klin. Wochenschr. 2016. 128(17–18). 641-8. doi: 10.1007/s00508-015-0768-9. PMID: 25787215.
  17. Karampela I., Sakelliou A., Vallianou N., Christodoulatos G.S., Magkos F., Dalamaga M. Vitamin D and Obesity: Current Evidence and Controversies. Curr Obes Rep. 2021. 10(2). 162-180. doi: 10.1007/s13679-021-00433-1. PMID: 33792853.
  18. Pankiv V.I., Yuzvenko T.Yu., Pankiv I.V. Type 2 diabetes mellitus and subclinical hypothyroidism: focusing on the role of cholecalciferol. Problems of Endocrine Pathology. 2019. (2). 46-51. doi: 10.21856/j-PEP.2019.2.07.
  19. Rosenfield R.L. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics. 2015. 136(6). 1154-65. doi: 10.1542/peds.2015-1430. PMID: 26598450.
  20. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Murad M.H., Weaver C.M.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011. 96(7). 1911-30. doi: 10.1210/jc.2011-0385. 
  21. Moselakgomo K.V., Van Staden M. Diagnostic comparison of Centers for Disease Control and Prevention and International Obesity Task Force criteria for obesity classification in South African children. Afr. J. Prim. Health Care Fam. Med. 2017. 9(1). e1-e7. doi: 10.4102/phcfm.v9i1.1383. PMID: 28893079; PMCID: PMC5594237.
  22. Szymczak-Pajor I., Miazek K., Selmi A., Balcerczyk A., Śliwińska A. The Action of Vitamin D in Adipose Tissue: Is There the Link between Vitamin D Deficiency and Adipose Tissue-Related Metabolic Disorders? Int. J. Mol. Sci. 2022. 23(2). 956. doi: 10.3390/ijms23020956. 
  23. Peña A.S., Witchel S.F., Hoeger K.M., Oberfield S.E., Vogiatzi M.G., Misso M. et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020. 18(1). 72. doi: 10.1186/s12916-020-01516-x. 
  24. Neven A.C.H., Laven J., Teede H.J., Boyle J.A. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin. Reprod. Med. 2018. 36(1). 5-12. doi: 10.1055/s-0038-1668085. 

Вернуться к номеру